X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (72941) 72941
Newsletter (1587) 1587
Magazine Article (128) 128
Book Chapter (98) 98
Newspaper Article (69) 69
Dissertation (64) 64
Government Document (33) 33
Conference Proceeding (26) 26
Publication (25) 25
Web Resource (11) 11
Journal / eJournal (7) 7
Reference (7) 7
Streaming Video (7) 7
Report (6) 6
Book / eBook (4) 4
Book Review (3) 3
Transcript (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (49312) 49312
female (36262) 36262
cyclophosphamide (30398) 30398
male (28315) 28315
middle aged (22649) 22649
adult (21737) 21737
cyclophosphamide - administration & dosage (20671) 20671
cyclophosphamide - therapeutic use (18191) 18191
antineoplastic combined chemotherapy protocols - therapeutic use (17269) 17269
oncology (16989) 16989
animals (15215) 15215
aged (15060) 15060
chemotherapy (11233) 11233
mice (9419) 9419
treatment outcome (9347) 9347
doxorubicin - administration & dosage (8814) 8814
hematology (8536) 8536
adolescent (8001) 8001
cancer (7920) 7920
vincristine - administration & dosage (7641) 7641
cyclophosphamide - pharmacology (7052) 7052
cyclophosphamide - adverse effects (6932) 6932
prognosis (6662) 6662
therapy (6240) 6240
combined modality therapy (6052) 6052
breast neoplasms - drug therapy (5891) 5891
child (5765) 5765
antineoplastic combined chemotherapy protocols - adverse effects (5506) 5506
drug therapy, combination (5439) 5439
antineoplastic combined chemotherapy protocols - administration & dosage (5284) 5284
transplantation (4993) 4993
prednisone - administration & dosage (4957) 4957
time factors (4902) 4902
retrospective studies (4881) 4881
immunosuppressive agents - therapeutic use (4617) 4617
rituximab (4587) 4587
care and treatment (4434) 4434
follow-up studies (4405) 4405
prednisone - therapeutic use (4346) 4346
vincristine - therapeutic use (4326) 4326
immunology (4164) 4164
rats (4142) 4142
research (3905) 3905
breast cancer (3819) 3819
methotrexate - administration & dosage (3779) 3779
disease-free survival (3757) 3757
doxorubicin (3753) 3753
child, preschool (3683) 3683
doxorubicin - therapeutic use (3641) 3641
drug administration schedule (3638) 3638
neoplasm staging (3560) 3560
remission induction (3535) 3535
antineoplastic agents - therapeutic use (3521) 3521
survival rate (3442) 3442
survival (3407) 3407
aged, 80 and over (3316) 3316
dose-response relationship, drug (3256) 3256
survival analysis (3228) 3228
fluorouracil - administration & dosage (3044) 3044
etoposide - administration & dosage (3030) 3030
pharmacology & pharmacy (2983) 2983
cisplatin - administration & dosage (2920) 2920
medicine & public health (2851) 2851
rheumatology (2838) 2838
medicine, general & internal (2836) 2836
analysis (2749) 2749
breast neoplasms - pathology (2713) 2713
risk factors (2669) 2669
young adult (2526) 2526
health aspects (2509) 2509
methotrexate - therapeutic use (2484) 2484
recurrence (2476) 2476
bone marrow transplantation (2409) 2409
prospective studies (2393) 2393
trial (2346) 2346
methotrexate (2270) 2270
lymphoma, non-hodgkin - drug therapy (2237) 2237
chemotherapy, adjuvant (2233) 2233
clinical trials as topic (2214) 2214
vincristine (2213) 2213
cyclophosphamide - toxicity (2211) 2211
disease (2172) 2172
immunosuppression (2146) 2146
lymphomas (2127) 2127
cisplatin (2125) 2125
antineoplastic agents - administration & dosage (2109) 2109
infant (2086) 2086
lymphoma, large b-cell, diffuse - drug therapy (2077) 2077
lung neoplasms - drug therapy (2045) 2045
immunotherapy (2038) 2038
hematopoietic stem cell transplantation (2023) 2023
ovarian neoplasms - drug therapy (2020) 2020
drug therapy (2016) 2016
doxorubicin - adverse effects (2015) 2015
toxicity (2011) 2011
stem cells (1932) 1932
leukemia (1920) 1920
children (1879) 1879
patients (1874) 1874
prednisone (1872) 1872
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (65481) 65481
German (2584) 2584
Japanese (2380) 2380
French (1433) 1433
Russian (1312) 1312
Chinese (831) 831
Spanish (730) 730
Italian (491) 491
Polish (422) 422
Portuguese (126) 126
Czech (107) 107
Korean (90) 90
Hungarian (79) 79
Dutch (71) 71
Danish (43) 43
Croatian (38) 38
Romanian (35) 35
Slovak (30) 30
Norwegian (29) 29
Bulgarian (26) 26
Hebrew (26) 26
Swedish (26) 26
Serbian (23) 23
Turkish (23) 23
Ukrainian (22) 22
Persian (16) 16
Finnish (14) 14
Lithuanian (5) 5
Arabic (2) 2
Bosnian (2) 2
Slovenian (2) 2
Icelandic (1) 1
Indonesian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The lancet oncology, ISSN 1470-2045, 2019, Volume 20, Issue 1, pp. 31 - 42
Journal Article
Rheumatology, ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2016, Volume 81, Issue 2, pp. 327 - 340
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 1, pp. 35 - 47
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
SURVIVAL | FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | RITUXIMAB | COMBINATION | FLUDARABINE | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2016, Volume 34, Issue 26, pp. 3141 - 3149
Purpose Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increasingly used in... 
DISEASE RISK INDEX | ALLOGENEIC TRANSPLANTATION | HODGKINS-LYMPHOMA | ONCOLOGY | BONE-MARROW | UNRELATED DONORS | IDENTICAL SIBLINGS | PERIPHERAL-BLOOD | UMBILICAL-CORD BLOOD | STEM-CELL TRANSPLANTATION | DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE | Lymphoma - surgery | Multivariate Analysis | Recurrence | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Male | HLA Antigens - genetics | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - adverse effects | Graft vs Host Disease - immunology | Lymphoma - mortality | Transplantation Conditioning - mortality | Young Adult | Haploidy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Registries | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Siblings | Calcineurin Inhibitors - administration & dosage | Histocompatibility Testing | Graft Rejection - prevention & control | Risk Factors | Lymphoma - immunology | Proportional Hazards Models | HLA Antigens - immunology | Lymphoma - genetics | Treatment Outcome | Disease-Free Survival | Adolescent | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Graft Rejection - immunology | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Graft Survival - drug effects | Histocompatibility | Bone2 | ORIGINAL REPORTS
Journal Article